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Abstract
Background—Plasmacytoid dendritic cells (pDCs) bridge innate and adaptive immune 
responses and are important regulators of immuno-inflammatory diseases. However, their role in 
atherosclerosis remains elusive. 
Methods and Results—Here, we used genetic approaches to investigate the role of pDCs in 
atherosclerosis. Selective pDC deficiency in vivo was achieved using CD11c-Cre x Tcf4–/flox BM 
transplanted into Ldlr–/– mice. Compared to control Ldlr–/– chimeric mice, CD11c-Cre x Tcf4–/flox 
mice had reduced atherosclerosis levels. To begin to understand the mechanisms by which pDCs 
regulate atherosclerosis, we studied chimeric Ldlr–/– mice with selective MHCII deficiency on 
pDCs. Significantly, these mice also developed reduced atherosclerosis compared to controls 
without reductions in pDC numbers or changes in conventional DCs. MHCII-deficient pDCs 
showed defective stimulation of ApoB100-specific CD4+ T cells in response to native LDL, 
whereas production of IFN-Į was not affected. Finally, the athero-protective effect of selective 
MHCII deficiency in pDCs was associated with significant reductions of pro-atherogenic T cell-
derived Ifn-J and lesional T cell infiltration, and was abrogated in CD4+ T cell-depleted animals. 
Conclusions—This study supports a pro-atherogenic role for pDCs in murine atherosclerosis and 
identifies a critical role for MHCII-restricted antigen presentation by pDCs in driving pro-
atherogenic T cell immunity. 
 
Key words: antigen, atherosclerosis, immune system, low-density lipoprotein, Plasmacytoid 
Dendritic cell, T cell, Interferon gamma 
DOI: 10.1161/CIRCULATIONAHA.114.011090 
3 
Introduction 
The first suggestion of adaptive immune activity in atherosclerosis came from the observation 
that HLA-DR was abundantly expressed in both immune and vascular cells of human 
atherosclerotic lesions 1. In the late 1980s, researchers reported that low-density lipoproteins 
(LDL) undergo oxidative modification in vivo and incite the generation of autoantibodies to 
modified LDL 2. This was followed in the mid 1990s by the discovery that CD4+ T lymphocytes 
from human atherosclerotic lesions recognize LDL-derived antigen in an HLA-DR-dependent 
manner 3 and by the identification of vascular dendritic cells (DCs) in human aortic intima 4. 
These seminal studies generated great interest in the immune mechanisms of atherosclerosis and 
were followed by 2 decades of intensive research into the roles of adaptive immune responses in 
disease initiation and progression. The studies defined the distinct roles of T lymphocyte subsets 
in the disease process 5: Th1-biased responses promote atherosclerosis whereas Tregs play a 
major counter-regulatory role and limit lesion inflammation and development, in part through the 
anti-atherogenic roles of IL-10 and TGF-E 5-7. Until recently, however, only a few studies 
addressed the contribution of DCs to the immune responses of atherosclerosis.  
DCs are detected in normal vessels 8, 9 preferentially in regions predisposed to 
atherosclerosis 8 where they accumulate lipid and contribute to the development of early fatty 
streaks 10. Besides these lipid scavenging properties, investigators have recently interrogated the 
roles of DCs in shaping atherosclerotic immune responses. DCs from normal and atherosclerotic 
vessels are able to process and present model antigens to CD4+ T cells in an MHCII-dependent 
manner 9, 11, 12. Adventitial DCs, like spleen and lymph node DCs, engage in sustained 
interactions with T cells, leading to T cell proliferation and cytokine secretion 11. However, the 
outcome of these interactions between conventional DCs (cDCs) and T cells on atherosclerosis is 
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still unclear. For example, genetic manipulations to expand or deplete the general pool of cDCs 
(and CD11c-expressing macrophages) using the CD11c-diptheria toxin receptor mouse did not 
reduce the development or progression of atherosclerosis 13. This disappointing and unexpected 
finding could be attributed either to a dominant role of cDCs in the modulation of cholesterol 
homeostasis or to the critical role of cDCs in the control of steady-state myelogenesis 14, blurring 
any potential role of DCs in adaptive immune responses to atherogenic stimuli. 
A few studies addressed the role of a distinct DC subset, plasmacytoid DCs (pDCs), in 
atherosclerosis. pDCs originate in the bone marrow, circulate in the blood and home to 
secondary lymphoid organs as well as sites of inflammation. pDCs are specialized type I 
interferon (IFNs) producers in response to virus infection and as such are major players in innate 
immune responses 15, 16. As the name suggests, pDCs are also capable of antigen presentation to 
T cells 17, 18, a function shown to be critical in some autoimmune disease models 19, although not 
in viral infection responses 20. pDCs are detected in normal and atherosclerotic vessels, both in 
humans and mice 21-23. Reduced blood levels of pDCs in humans are suggested to reflect 
increased plaque infiltration and correlate with coronary artery disease 24, 25. Vascular pDCs are 
able to present antigen to T cells in vitro 23 and can load a model peptide on MHCII in vivo 26. 
However, the outcome and relevance to atherosclerosis remains uncertain. While some studies 
suggested a pro-atherogenic role for pDCs 23, 26, other investigators reported an athero-protective 
effect 22. The reasons for these discrepancies remain unknown and the mechanisms through 
which pDCs alter immune responses in atherosclerosis remain elusive. In particular, each of the 
above-mentioned atherosclerosis studies used antibody-mediated depletion of pDCs targeting 
PDCA1 (BST-2/CD317), which is not entirely specific for pDCs 27, especially in inflammatory 
settings. Therefore, alternative approaches are required to definitively address the role of pDCs 
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and the mechanisms through which they modulate immune-mediated diseases. Here, we used 
selective genetic approaches to interrogate the role of pDCs in the development of murine 
atherosclerosis. We identify a critical role for MHCII expression on pDCs in driving pro-
atherogenic T cell immunity. The results may have broad implications for the understanding of 
the immune mechanisms of atherosclerosis and other related immune diseases.  
Methods
An expanded methods section is available in the online supplementary material. 
Mice
All experiments were approved by the Home Office, UK. pIII+IV–/– mice were previously 
described 28. 
Flow cytometry 
Single cell suspensions were stained with fluorophore-conjugated antibodies (Supplemental
Table 1) and analyzed using LSRII Fortessa (BD) or CyAN ADP (Beckman Coulter) flow 
cytometers using the gatings shown in Supplemental Figure 1.  
Analysis of in vivo antigen presentation 
The EĮ-GFP/Y-Ae system was described previously 26. To determine the anatomical location of 
the antigen processing pDCs, Ldlr–/– mice were injected with DQ-OVA. After 1 h the aortic sinus 
was harvested for immunohistochemical analysis. For in vivo OT-II stimulation, C57BL6 mice 
were injected with CFSE –labeled OT-II T cells, then injected with ovalbumin-loaded pDCs. 
OT-II T cell proliferation was assessed after 3 days by flow cytometry. 
In vitro dendritic cell culture 
Bone marrow (BM) pDCs or spleen CD11c+ cells were isolated using an AutoMACS Pro 
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separator. Supplemental Figure 2 shows pDC purity. For cytokine production, purified pDCs 
were treated with CpG oligonucleotides or control GpC. For antigen presentation assays, DCs 
were preincubated with antigen (OVA or native LDL) then with antigen-specific T cells. T cell 
activation was measured by proliferation or Il-2 production. 
Statistics
Results were presented as mean ± S.E. They were analyzed in GraphPad Prism (La Jolla, CA, 
USA) using unpaired t-test, non-parametric Mann-Whitney U test, one way analysis of variance 
or repeated measures two-way analysis of variance, as appropriate. P value (two-sided) of <0.05 
was considered significant. 
Results
Selective blockade of pDC development limits atherosclerosis in Ldlr–/– mice. 
Basic helix-loop-helix transcription factor E2-2/Tcf4 is an essential regulator of the pDC lineage, 
and CD11c-restricted deletion of Tcf4 (as in CD11c-Cre x Tcf4–/flox mice) selectively blocks pDC 
development and maintenance 20, 29. The phenotype of these ‘pDC-less’ mice has been previously 
reported, demonstrating for example that they display selective defects in pDC responses and are 
susceptible to MHV infection 20. We therefore reconstituted lethally irradiated Ldlr–/– mice with 
either CD11c-Cre x Tcf4–/flox (conditional Tcf4 deletion in CD11c+ cells, designated Tcf4-cKO 
thereafter) or CD11c-Cre x Tcf4+/flox (control, designated Tcf4-WT thereafter) BM 20. After 
recovery, mice were put on high fat diet (HFD) for 8 weeks. Ldlr–/– Tcf4-cKO mice displayed 
marked reduction of pDC (CD11c+ B220+ PDCA1+ cells; see Supplemental Figure 1 for an 
example of gating strategy) numbers in blood, spleen, lymph nodes (Figure 1A) and aortas 
(Supplemental Figure 3A) compared with control Ldlr–/– Tcf4-WT mice. The depletion was 
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selective for pDCs, as we found no difference in other cell populations (T cells, B cells, 
monocytes and neutrophils) in blood or lymphoid organs (Supplemental Figure 3B-3D). Of 
note, contrary to the phenotype of cDC-less mice 14, blockade of pDC development did not alter 
myelogenesis, despite chronic feeding with a HFD (Supplemental Figure 3D). We also assessed 
the numbers of other DC subtypes. As previously reported for Tcf4-cKO mice 29, a B220lo cDC-
like (CD11chi MHCII+) population that derives from converted Tcf4–/– pDCs was increased in the 
spleen and lymph nodes (Figure 1B), consistent with the role of Tcf4 in maintaining the cell fate 
of mature pDC through active opposition of a cDC ‘default’ program. We also found increased 
numbers of CD11chi MHCII+ B220– DCs in spleens and lymph nodes of Ldlr–/– Tcf4-cKO mice 
compared with controls (Figure 1C). The proportions of CD11b+ and CD8Į+ cells within this 
population were not significantly changed (data not shown). Loss of pDCs and increase of cDCs 
may have effects on regulatory T cells. However we found no differences in the levels of spleen 
regulatory T cells between groups (Supplemental Figure 3E). 
Animal weight (Figure 1D), plasma HDL-cholesterol (2.46 ± 0.36 mM vs 2.81 ± 0.22 
mM; p=0.64) and triglycerides (5.51 ± 0.73 mM vs 5.29 ± 0.54 mM; p=0.45) were similar 
between the 2 groups of mice. However, Ldlr–/– Tcf4-cKO mice showed a significant, although 
relatively small, increase of plasma total cholesterol levels in comparison with Ldlr–/– Tcf4-WT 
animals (Figure 1D). A similar phenotype has previously been reported in cDC-depleted Ldlr–/– 
or Apoe–/– mice 13, suggesting a similar potential role for pDCs in cholesterol metabolism. 
Previously, increased cholesterol in cDC-depleted mice was proposed to explain the lack of 
effect of cDC depletion on atherosclerosis 13. It is therefore remarkable that despite higher 
plasma cholesterol levels, pDC-less Ldlr–/– Tcf4-cKO mice showed significantly reduced 
atherosclerosis compared with Ldlr–/– Tcf4-WT controls (Figure 1E). Reduced lesion 
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development was associated with a substantial reduction in plaque T cell accumulation (Figure
1F). Thus, blockade of pDC development substantially limits pro-atherogenic adaptive 
immunity, indicating a prominent role in disease development. 
MHCII-restricted antigen presentation to T cells by pDCs. 
We next addressed the potential functions of pDCs that may be influencing atherosclerosis. In 
general, pDCs have so far been found to be less potent stimulators of CD4+ T cells in the 
presence of cognate antigen than cDCs or inflammatory/bone-marrow derived DCs. 
Nevertheless, pDCs are capable of antigen presentation in a number of conditions 19, 26, 30. We 
therefore addressed the role of MHCII-dependent functions of pDCs. Aortic pDCs from Apoe–/– 
mice have already been shown to take up injected ED antigen and present it in the context of 
MHCII 26. Aortic pDCs from Ldlr–/– mice are also capable of ED antigen presentation (Figure
2A). Staining with the Y-Ae antibody (which recognizes the EĮ peptide specifically in the 
context of MHCII I-Ab) was readily detectable on aortic pDCs from chow and HFD-fed Ldlr–/– 
mice injected with ED-GFP but not those injected with PBS (Figure 2A). In addition, after 
injection of DQ-OVA (a self-quenched conjugate of ovalbumin that exhibits bright green 
fluorescence upon proteolytic degradation), cells in the aortic root plaques of Ldlr–/– mice 
staining positive for the pDC marker Siglec-H were also positive for processed DQ-OVA 
(Figure 2B).  
We then investigated the ability of pDCs to present the model antigen ovalbumin to 
purified OVA-specific OT-II CD4+ T cells, using Mhcii–/– mice to confirm the antigen 
dependency. Both WT splenic cDCs and BM pDCs induced T cell proliferation in the presence 
of OVA (Figure 2C). As expected, pDCs stimulated OT-II T cells to a lesser extent, but the 
majority of their effect was dependent on MHCII, since there was significantly less T cell 
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proliferation in the presence of MHCII-deficient pDCs (Figure 2C). 
To target MHCII selectively in pDCs, we took advantage of the cell and tissue-specific 
promoters of the MHCII transactivator (CIITA), pI, pIII, and pIV, which specifically controls 
expression of MHCII genes and a handful of antigen-presentation related genes19. The pI 
promoter controls MHCII expression in cDCs, macrophages and microglia, pIII selectively 
controls MHCII expression in pDCs and B cells, whereas pIV controls MHCII expression by 
thymic epithelial cells and immune-stimulated non-hematopoietic cells 28. Therefore, mice 
receiving BM cells lacking pIII and pIV (pIII+IV–/–) allow the study of the role of MHCII-
restricted antigen presentation by pDCs and B cells. We backcrossed pIII+IV–/– mice with B cell 
deficient μMT mice in order to generate (“μMT:pIII+IV–/–”) mice lacking MHCII-restricted 
antigen presentation only by pDCs. Compared to μMT controls, μMT:pIII+IV–/– pDCs did not 
express detectable MHCII above isotype control staining in flow cytometry analysis 
(Supplemental Figure 4A). Firstly, we studied the role of selective MHCII deficiency in pDCs 
on antigen-specific T cell activation in culture. Importantly, μMT:pIII+IV–/– pDCs secreted 
inflammatory cytokines at normal levels in response to CpG activation (Supplemental Figure 
4B), confirming that their innate functions were intact 19.  
To confirm a defect in antigen presentation by pDCs in the absence of pIII+IV, we 
repeated the OT-II stimulation experiments in the presence of either PMT:pIII+IV–/– or 
PMT:pIII+IV+/+ control BM pDCs. T cell proliferation in the presence of OVA was significantly 
attenuated in PMT:pIII+IV–/– BM pDCs compared to PMT pDCs (Figure 2D). These 
experiments were conducted in the continuing presence of ovalbumin protein. When ovalbumin 
was removed before addition of OT-II T cells (OVA pulse), the effect of pIII+IV deficiency on 
pDCs was much greater (Figure 2E). To confirm an antigen presentation defect in vivo, we 
DOI: 10.1161/CIRCULATIONAHA.114.011090 
10 
adoptively transferred CFSE-labeled OT-II T cells into C57/BL6 mice and, after 24h, injected 
μMT or μMT:pIII+IV–/– pDCs pre-incubated with ovalbumin into the footpad. OT-II T cell 
proliferation was detectable in the popliteal lymph node of the injected hindlimb of μMT pDC 
recipients, but no proliferation was detected in μMT:pIII+IV–/– pDC recipients above that seen in 
the uninjected hindlimb popliteal lymph nodes (Figure 2F). 
MHCII-restricted presentation of native LDL to T cells by pDCs. 
To investigate an antigen with relevance to atherosclerosis, we utilized a T cell hybridoma 
specific for human native LDL (nLDL) cloned from hApoB100tg x Ldlr–/– mice, originally 
described by Hermansson et al. (see online-only Supplemental Methods). Antigen-specific 
stimulation of the T cell hybridoma was measured by enhanced production of IL-2 after 15h co-
culture with cDCs or pDCs pre-incubated with nLDL. We confirmed a defect in nLDL-specific 
T cell activation in PMT:pIII+IV–/– BM pDCs compared to μMT pDCs, but no differences 
between cDCs from the two genotypes (Figure 2G). Importantly, pDCs stimulated nLDL-
specific T cells to the same extent as cDCs (Figure 2G), suggesting an enhanced ability to 
present this type of antigen compared to the model antigen OVA (Figure 2C). The results 
suggest a prominent and previously unsuspected role for pDCs in MHCII-restricted presentation 
of LDL-derived epitopes to CD4+ T cells. 
MHCII expression on pDCs promotes atherogenesis. 
We therefore examined the role of selective deletion of MHCII in pDCs on the adaptive immune 
response to HFD and its consequence on the development of atherosclerosis. Lethally irradiated 
Ldlr–/– mice reconstituted with either PMT:pIII+IV–/– or control PMT BM were analyzed after 4 
weeks recovery followed by a HFD for 6 weeks. Animal weights (29.69 g ± 0.94 vs 30.77 g ± 
0.97) and total plasma cholesterol (7.49 ± 0.79 g/l vs 7.71 ± 0.52 g/l, in PMT:pIII+IV+/+o Ldlr–
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/– and PMT:pIII+IV–/–o Ldlr–/–mice, respectively, p=0.82) were similar between groups. 
Numbers of blood monocytes and neutrophils were also comparable between the 2 groups of 
mice (Supplemental Figure 5A). Unlike Tcf4-cKO mice, pIII+IV deletion had no effect on the 
distribution of pDCs (Figure 3A) or cDCs (Figure 3B).  However, PMT:pIII+IV–/– o Ldlr–/– 
mice displayed a selective abrogation of MHCII expression on pDCs (Figure 3C). MHCII 
expression on cDCs was unaltered (Supplemental Figure 5B) and there were no differences in 
cDC activation markers including CD40, CD80 and CD86 between the 2 groups of mice (data 
not shown). Interestingly, aortic root lesion size was significantly reduced in PMT:pIII+IV–/–o 
Ldlr–/– mice (Figure 3E). We therefore assessed the effect of this pDC-restricted MHCII 
deficiency on T cell responses. pIII+IV deletion had no impact on Tregs levels in the spleen and 
did not alter their suppressive potential (Supplemental Figures 5C and 5D). However, we 
found a significant reduction of pro-atherogenic Ifn-J producing CD4+ T cells (but no differences 
in Il-17+ T cells) in PMT:pIII+IV–/– o Ldlr–/– compared with PMT:pIII+IV+/+o Ldlr–/– mice, 
using intracellular flow cytometry staining on freshly isolated spleen T cells (Figure 3D and 
Supplemental Figures 5E and 5F). Importantly, there was a substantial decrease of vascular T 
cell infiltration in lesions of PMT:pIII+IV–/–o Ldlr–/– mice (Figure 3F). Thus, MHCII 
expression by pDCs is required to drive a pro-atherogenic T cell immunity. 
The pro-atherogenic effect of pDC-selective MHCII expression requires the presence of 
CD4+ T cells. 
To further substantiate the T cell-dependent effects of pDC MHCII, we repeated the experiment 
with additional groups of PMT:pIII+IV+/+o Ldlr–/– and PMT:pIII+IV–/–o Ldlr–/– receiving a 
depleting anti-CD4 antibody (see Supplemental Methods) during 8 weeks of HFD. As expected, 
PMT:pIII+IV–/– o Ldlr–/– mice displayed a selective abrogation of MHCII expression on pDCs 
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(Figure 4A), and T cell depletion was substantial in anti-CD4-treated mice (Figure 4B) and 
maintained throughout the experiment (data not shown). Animal weights were similar between 
groups (Figure 4C). pIII+IV deficiency had no effect on serum cholesterol, whereas CD4+ T cell 
depletion led to a 25% decrease (Figure 4D), as previously reported in Apoe–/–/Rag1–/– and Ldlr–
/–/Rag1–/– mice 31. CD4 depletion led to a 50% decrease in atherosclerosis in PMT:pIII+IV+/+o 
Ldlr–/– mice (Figure 4E), which is consistent with the phenotype of Rag1-deficient animals 31, 32 
and the pro-atherogenic role of CD4+ T cells 33. Remarkably, CD4 depletion did not reduce 
lesion development in PMT:pIII+IV–/–o Ldlr–/– mice (despite reduced cholesterol), indicating 
that pDC MHCII deficiency had abrogated the pro-atherogenic properties of CD4+ T cells 
(Figure 4E). The results strongly support an MHCII-CD4+ T cell dependent pathway for the pro-
atherogenic effect of pDCs. 
Selective MHCII expression on pDCs promotes atherogenesis in the presence of B cells. 
B cells are known to significantly regulate atherosclerosis 34-36, and pDCs might influence B cell 
responses. Since the above pIII+IV–/– experiments were performed in B cell-deficient animals, 
we generated B cell-sufficient mice with selective abrogation of MHCII in pDCs. To this aim, 
lethally irradiated Ldlr–/– mice were reconstituted with a mixture of 80% BM from PMT:pIII+IV–
/– mice and 20% BM from WT mice. In this case, B cells only develop from the 20% WT BM 
and are MHCII+. However, 80% of pDCs will be generated from the PMT:pIII+IV–/– BM and 
should therefore be deficient in MHCII. Control Ldlr–/– mice were reconstituted with a mixture 
of 80% BM from PMT mice and 20% BM from WT (all B cells and pDCs are MHCII+). After 
recovery, mice were fed a HFD for 8 weeks. Proportions of pDCs, cDCs, T and B cells were 
similar between the 2 groups of mice (Supplemental Figure 6) and only pDCs were defective in 
MHCII expression (Figure 5A-C). This pDC-specific MHCII deficiency again resulted in a 
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significant reduction of lesion size (Figure 5D) and 70% reduction of vascular T cell infiltration 
(Figure 5E) along with reduced systemic levels of Ifn-J (Figure 5F) despite no change of 
plasma cholesterol levels (μMT/WT: 10.96 ± 0.61 g/l, PMT:pIII+IV–/–/WT: 9.91 ± 0.58 g/l, 
p=0.22). 
 
Discussion
Atherosclerosis development is driven by both innate and adaptive immune responses. Recent 
studies further highlighted the role played by LDL in driving antigen-specific pro-atherogenic T 
cell immunity 37. T cell-mediated responses and disease severity were shown to be highly 
dependent on cDC subtype. CCL17-expressing DCs restrain Treg responses and promote 
atherosclerosis 38 whereas Flt3-dependent CD103+ DCs and CD11c-restricted MyD88 signaling 
sustain athero-protective Tregs 39, 40, as do DCs that were manipulated to exert tolerogenic 
activity 41. However, whether these distinct effects require antigen presentation by DC subsets 
remains elusive. Reduction of atherosclerosis in mice lacking MHCII-associated invariant chain 
CD74 42 is frequently cited as evidence for a potential role of antigen presentation in 
atherosclerosis. However, CD74-deficient mice display defective CD4+ T cell selection and 
massive reduction of thymic and spleen CD4+ T cells already in the absence of atherosclerosis 43, 
precluding any direct conclusion regarding the distinct role of antigen presentation in disease 
development. Therefore, the in vivo role of MHCII-restricted antigen presentation by cDCs in the 
development of atherogenic immunity remains unknown. In addition, as mentioned above, 
sustained total cDC depletion did not result in athero-protection. 
Recent studies therefore focused on the pDC subset and its potential role in 
atherosclerosis, but discrepant results and mechanisms were reported 22, 23, 26. As an alternative to 
DOI: 10.1161/CIRCULATIONAHA.114.011090 
14 
the antibody depletion strategy, used in all 3 previous studies that addressed the role of pDCs in 
atherosclerosis, we used genetically-modified mice with selective deficiency in pDCs. Our 
results clearly show that the development of atherosclerosis is reduced in pDC-less mice, which 
strongly argues in favor of a major role of pDC-mediated immunity in driving the atherogenic 
process.  
A limitation of the depleting strategies mentioned above and the use of pDC-less mice is 
that they allow no conclusion about innate versus adaptive functions of pDCs in atherosclerosis. 
Indeed, besides their major role in shaping innate immune responses, pDCs have also been 
suggested to function as antigen presenting cells (APCs). They are capable of antigen cross-
presentation to CD8+ T cells 44, 45, express MHCII molecules and acquire a mature phenotype to 
internalize, process and present antigen to CD4+ T cells 17, 18. However, such APC function could 
not be observed in vivo using models of virus infection and antibody-mediated pDC depletion 46. 
It appears that under conditions of acute viral infection, pDCs mainly act via type I IFN 
production 20, whereas the contributions of innate versus adaptive immune functions of pDCs to 
chronic immune diseases require more investigation. An APC function was recently 
demonstrated in a model of experimental autoimmune encephalomyelitis (EAE), where pDCs 
inhibited T cell-mediated autoimmunity 19. Whether this result could be translated to other 
(auto)immune-mediated diseases was still unknown. Here, we addressed this question in the 
context of atherosclerosis by generating mice with selective abrogation of MHCII expression in 
pDCs and provided strong evidence for a critical role of MHCII-restricted antigen presentation 
by pDCs in driving pro-atherogenic T cell responses. The results are of high importance and 
should prompt a re-assessment of the differential roles of pDCs and cDCs in shaping adaptive 
immune responses during atherogenesis. 
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Our results might appear in contradiction with the tolerogenic role assigned to pDCs in 
other settings. However, previous studies on the role of pDCs in antigen-specific CD4+ T cell 
responses in vivo used a disease-unrelated model antigen, i.e. OVA 30, which might not faithfully 
reproduce the regulation of disease-specific immune responses. In other studies, Irla et al. 
reported an inhibitory role of MHCII-restricted antigen presentation by pDCs in a mouse model 
of EAE 19. However in the EAE model, the disease process is initiated after active immunization 
with antigen in association with adjuvants, which is different from the spontaneous development 
of adaptive immune responses to endogenous LDL-derived antigens in the atherosclerosis model. 
APC function of pDCs might differ between these 2 different ways of induction of adaptive 
immunity. Finally, the outcome of antigen presentation by pDCs might depend on the nature of 
the presented antigen and the local microenvironment where presentation occurs. For example, 
exposure to oxidized LDL selectively enhanced the surface expression of the scavenger receptor 
CD36, with enhanced phagocytic function of pDCs and increased capacity to prime antigen-
specific T-cell responses 23. It is conceivable that under basal non-inflammatory conditions, LDL 
presentation by pDCs induces tolerogenic adaptive immune responses, which then gradually 
switches towards effector responses with the progressive high load of cholesterol and 
environmental inflammatory stimuli. This hypothesis merits further investigation. 
It should be noted that the present work addressed the role of pDCs in early 
atherosclerosis, at which point pro-atherogenic T cell immunity greatly influences 
atherosclerosis development in mice 32. Additional studies are needed to determine the 
contribution of pDC-mediated immunity at later stages of disease development. Since pDCs and 
T cells infiltrate both early and advanced atherosclerotic lesions in humans 21-25, 47, 48, we 
speculate that our results will also bear relevance to the human disease. However, direct testing 
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of this hypothesis is still required. 
In conclusion, we present new evidence that MHCII-restricted antigen presentation by pDCs 
drives pro-atherogenic T cell immunity. The results shed new light on the role of adaptive 
immune responses in atherosclerosis and may have implications for the design of specific 
therapeutic strategies. 
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Figure Legends: 
Figure 1. Conditional Tcf4 deficiency in CD11c+ cells reduces tissue pDC levels and decreases 
atherosclerosis. Ldlr–/– mice transplanted with Tcf4-WT or Tcf4-cKO BM were fed a HFD for 8 
weeks. A-C. Lymphoid tissue and blood levels of pDCs (A), B220lo cDCs (B) and cDCs (C). 
See methods for gating strategy. Results representative of 2 separate experiments with similar 
results. D. Terminal weights and serum total cholesterol levels. E. Representative images of oil 
red O-stained aortic root lesions (bar represents 100 ȝm). Quantification of total plaque area at 
the aortic root in 10 serial sections beginning at the start of the aortic valves (0 ȝm). Data 
represents mean ± S.E. at each position (n=10/group). Statistical significance determined by two-
way ANOVA. F. Quantification of plaque CD3+ cells/mm2 in the aortic root. For each figure, 
significant differences between groups are indicated by p values. 
 
Figure 2. Antigen presentation by pDCs in vivo and in vitro. A. Chow or HFD-fed Ldlr–/– mice 
injected with EĮ-GFP (or PBS) and whole aortas were digested and analysed by flow cytometry 
for pDC uptake of EĮ-GFP using Y-Ae antibody. Data are from 4 pooled aortas/group. B. pDCs 
detected by staining for Siglec-H (red) in the aortic sinus of Ldlr–/– mice were able to uptake and 
process DQ-OVA [green or yellow (green +  red)]. Cell nuclei are stained by DAPI (blue). A: 
Adventitia, M: Media, P: Plaque. Representative images from analysis of 5 mice. C. Proliferation 
of OT-II CD4 T cells after incubation with spleen CD11c+ from WT mice or BM pDCs from WT 
and MHCII–/– mice incubated with or without 100 μg/ml ovalbumin. Data representative of 2 
separate experiments. *p<0.05. D. OT-II CD4 T cell proliferation after incubation with pDCs 
from μMT or μMT:pIII+IV–/– mice with or without 100 μg/ml ovalbumin continuously. *p<0.05. 
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E. OT-II CD4 T cell proliferation after incubation with pDCs from μMT or μMT:pIII+IV–/– mice 
with pre-incubated with or without 100 μg/ml ovalbumin and/or CpG-B (5 μg/ml) prior to 
addition of OT-II T cells only.*p<0.05. F. OT-II T cell proliferation in vivo (% of total OT-II) 
after injection of ova-loaded ȝMT or ȝMT:pIII+IV–/– pDCs in popliteal lymph nodes from the 
uninjected control (Con) or injected (Inj) hindlimbs. *p<0.05. G. Activation of human ApoB100-
specific T cell hybridoma (48-5T), measured by Il-2 secretion, after 15h co-culture with spleen 
CD11c+ cells or BM pDCs from μMT or μMT:pIII+IV–/– mice with or without native human 
LDL (25 μg/ml). Data representative of at least 2 experiments in D and E, and 4 experiments in 
G with similar results. *p<0.05. 
 
Figure 3. Conditional MHCII deficiency in pDCs decreases atherosclerosis in B cell-deficient 
mice. Ldlr–/– mice transplanted with ȝMT or ȝMT: pIII+pIV–/– BM were fed a HFD for 6 weeks. 
Results representative of 3 separate experiments with similar results. A. Lymphoid tissue and 
blood levels of pDCs. See methods for gating strategy. B. Lymphoid tissue levels of cDCs and 
B220lo cDCs. See methods for gating strategy. C. Mean fluorescence intensity (MFI) of MHCII 
staining on pDCs. D. Percentage of spleen CD4+ T cells positive for IFN-Ȗ by intracellular flow 
cytometry (see methods). N=5/group. See also Supplemental Figure 4D. E. Representative 
images of oil red O stained lesions (bar represents 100 ȝm). Quantification of total plaque area at 
the aortic root in 10 serial sections beginning at the start of the aortic valves (0 ȝm). Data 
represents mean at each position ± S.E. (n=7 ȝMT, 9 ȝMT:pIII+IV–/–). Statistical significance 
determined by two-way ANOVA. F. Quantification of plaque and adventitial CD3+ cells in the 
aortic root. For each figure, significant differences between groups are indicated by p values. 
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Figure 4. The protective effect of MHCII deficiency in pDCs is dependent on CD4+ T cells. 
Ldlr–/– mice transplanted with ȝMT or ȝMT: pIII+pIV–/– BM were fed a HFD for 8 weeks and 
injected every 10 days with either PBS or a CD4 T cell depleting antibody (ĮCD4). A. Mean 
fluorescence intensity (MFI) of MHCII staining on pDCs. *p<0.05. B. Blood CD4+ T cell levels 
before (Day 0) and at Day 20. *p<0.05. C+D. Final body weights and serum total cholesterol. 
*p<0.05. E. Quantification of total plaque area at the aortic root in 10 serial sections beginning at 
the start of the aortic valves (0 ȝm). Data represents mean at each position ± S.E. (n=11 
ȝMT/PBS, 9 ȝMT:pIII+IV–/–/PBS, 10 μMT/ĮCD4, 11 μMT:pIII+IV–/–/ĮCD4). Statistical 
significance determined by two-way ANOVA. 
 
Figure 5. Conditional MHCII deficiency in pDCs decreases atherosclerosis in B cell- sufficient 
mice. A-C. Mean fluorescence intensity (MFI) of MHCII staining on pDCs (A), B cells (B) or 
cDCs (C). D. Representative images of plaque area. Bar represents 100 ȝm. Quantification of 
total plaque area at the aortic root in 10 serial sections beginning at the start of the aortic valves 
(0 ȝm). Data represents mean ± S.E at each position (n=10 WT pDC group, 12 pIII+IV–/– pDC 
group). E. Quantification of CD3+ cells in the vascular lesions. F. Serum IFN-Ȗ quantified by 
luminex assay (see methods). For each figure, significant differences between groups are 
indicated by p values. 
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